Comparison of Bleeding Risk Between Rivaroxaban & Apixaban

Status Completed

Clinical Trial Summary

This vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood thinners for the treatment of blood clots. Half of the patients will receive apixaban and half will receive rivaroxaban. The main objective is to determine the feasibility of patient recruitment and resources required to follow enrolled patients and inform for a larger, multi-centered trial and to assess which one is safer.

Clinical Trial Description

Recently developed new oral anticoagulants (OAC) overcome some of the limitations of established therapy with vitamin K antagonists (VKA) and low molecular weight heparin (LMWH) for treatment of acute venous thromboembolism (VTE), due to ease of administration and more predictable pharmacokinetic properties. Many clinical questions about the new OAC remain unanswered because there have not been direct head-to-head comparison trials. For example, although studies have shown that rivaroxaban and apixaban are at least as effective and safe as LMWH and VKA, meta-analyses suggest that apixaban may be associated with lower bleeding risk. Concerns about the potential impact of medication non-adherence have been raised. Compliance with twice daily medications (e.g. apixaban) is often worse than once daily medications (e.g. rivaroxaban). Both of these medications are approved by Health Canada for treatment of VTE yet there is genuine uncertainty about which of the two direct OAC confer the best risk-to-benefit ratio.This is a multi-centre, prospective randomized open blinded end-point (PROBE) trial assessing clinical feasibility for a larger multi-centered trial comparing bleeding outcomes using apixaban vs. rivaroxaban for treatment of acute VTE. The primary objective of the study is to determine if it is feasible to conduct a large randomized multicenter trial comparing apixaban vs. rivaroxaban for the treatment of acute VTE. The secondary objectives are to assess safety and superiority of apixaban vs rivaroxaban. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02559856
Study type	Interventional
Source	Ottawa Hospital Research Institute
Contact
Status	Completed
Phase	Phase 4
Start date	May 2016
Completion date	February 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05347550` - Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients	N/A
Enrolling by invitation	`NCT05794165` - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism	Phase 2
Completed	`NCT02379806` - The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study	Phase 3
Recruiting	`NCT03691753` - Safety and Efficacy Study of Fitaya Vena Cava Filter	N/A
Completed	`NCT02197416` - Safety of Dabigatran Etexilate in Blood Clot Prevention in Children	Phase 3
Recruiting	`NCT05378035` - DOAC in Chinese Patients With Atrial Fibrillation
Recruiting	`NCT05171075` - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE	Phase 3
Completed	`NCT01895777` - Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)	Phase 3
Completed	`NCT05897697` - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Completed	`NCT04736719` - Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Completed	`NCT04736420` - Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Completed	`NCT04735523` - Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Completed	`NCT02829957` - RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding	Phase 2/Phase 3
Completed	`NCT02912234` - Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants	Phase 1
Completed	`NCT02746185` - Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban	Phase 3
Completed	`NCT02334007` - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery	Phase 1/Phase 2
Completed	`NCT02661568` - Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)	N/A
Completed	`NCT02223260` - Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age	Phase 2
Completed	`NCT01976988` - Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery	Phase 3
Completed	`NCT01431456` - Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban — COBRRA Pilot

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms